Sarepta Continues To Show Results In DMD, But Is It Enough?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The biotech announced positive results from a small Phase IIb study, but investors are wary and it’s still unclear whether regulators will consider the data to be clear cut enough for approval.